All the cases show that the most important factor of success depends on whether such products or services can provide higher response rate and have relevant support of pharmacoeconomics studies.

• 另外，未来药物基因体相关的临床试验将会是一波新兴的产业机会，不但将有助于降低成本，并且提供挽救临床试验失败药物的机会。